A Bayesian pick-the-winner design in a randomized phase II clinical trial.


PURPOSE Many phase II clinical trials evaluate unique experimental drugs/combinations through multi-arm design to expedite the screening process (early termination of ineffective drugs) and to identify the most effective drug (pick the winner) to warrant a phase III trial. Various statistical approaches have been developed for the pick-the-winner design but have been criticized for lack of objective comparison among the drug agents. METHODS We developed a Bayesian pick-the-winner design by integrating a Bayesian posterior probability with Simon two-stage design in a randomized two-arm clinical trial. The Bayesian posterior probability, as the rule to pick the winner, is defined as probability of the response rate in one arm higher than in the other arm. The posterior probability aims to determine the winner when both arms pass the second stage of the Simon two-stage design. RESULTS When both arms are competitive (i.e., both passing the second stage), the Bayesian posterior probability performs better to correctly identify the winner compared with the Fisher exact test in the simulation study. In comparison to a standard two-arm randomized design, the Bayesian pick-the-winner design has a higher power to determine a clear winner. In application to two studies, the approach is able to perform statistical comparison of two treatment arms and provides a winner probability (Bayesian posterior probability) to statistically justify the winning arm. CONCLUSION We developed an integrated design that utilizes Bayesian posterior probability, Simon two-stage design, and randomization into a unique setting. It gives objective comparisons between the arms to determine the winner.

DOI: 10.18632/oncotarget.19088

Cite this paper

@article{Chen2017ABP, title={A Bayesian pick-the-winner design in a randomized phase II clinical trial.}, author={Dung-Tsa Chen and Po-Yu Huang and Hui-Yi Lin and Alberto A. Chiappori and Dmitry I Gabrilovich and Eric B. Haura and Scott J. Antonia and Jhanelle Elaine Gray}, journal={Oncotarget}, year={2017} }